Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Approvals Action
Gilead's Viread replacement registered
Gilead has won registration for chronic hepatitis B treatment Vemlidy, its replacement drug for Viread in that indication, which will soon be facing generic competition.
Pipeline Monitor
Celgene scores with old and new drugs
Celgene's Revlimid has won an additional indication in the US while the company's potential blockbuster, ozanimod, has enjoyed success in a head-to- had trial against Biogen's Avonex.
Debating Point
Expert games not very convincing
Both sides in the battle over the future of biosimilar prescribing in Australia have been rolling out their foreign experts but it's hard to see how fly-in, fly-out expertise can influence a government facing multiple budget management problems at home.